Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 CAD | -0.81% | +3.04% | +17.53% |
Sales 2024 * | 346M 254M 21.18B | Sales 2025 * | 356M 261M 21.82B | Capitalization | 618M 454M 37.87B |
---|---|---|---|---|---|
Net income 2024 * | 2M 1.47M 122M | Net income 2025 * | 13M 9.54M 796M | EV / Sales 2024 * | 1.79 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
214
x | P/E ratio 2025 * |
59.8
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.64% |
Latest transcript on Knight Therapeutics Inc.
1 day | -0.81% | ||
1 week | +3.04% | ||
Current month | +5.72% | ||
1 month | +5.90% | ||
3 months | +9.32% | ||
6 months | +17.76% | ||
Current year | +17.53% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 01/13/01 |
Jonathan Goodman
FOU | Founder | 56 | 01/13/01 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 20/16/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 06/14/06 |
Jonathan Goodman
FOU | Founder | 56 | 01/13/01 |
Robert Lande
BRD | Director/Board Member | 61 | 01/13/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
15/24/15 | 6.1 | -0.81% | 55,528 |
14/24/14 | 6.15 | +1.65% | 89,025 |
13/24/13 | 6.05 | +1.85% | 82,284 |
10/24/10 | 5.94 | -2.62% | 90,840 |
09/24/09 | 6.1 | +3.04% | 224,684 |
Delayed Quote Toronto S.E., May 16, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.53% | 455M | |
+14.61% | 78.37B | |
+11.98% | 9.08B | |
-12.85% | 5.06B | |
+54.35% | 4.85B | |
+16.71% | 2.37B | |
-20.85% | 2.36B | |
+24.62% | 2.27B | |
-29.25% | 2.22B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock